AbCellera Bets ABCL635 as Best-in-Class Non-Hormonal Hot-Flash Therapy
AbCellera’s Phase 2 readout for ABCL635 in postmenopausal women showed a statistically significant, placebo-adjusted reduction of 5.3 daily hot flashes by Week 4 (8.8/day with ABCL635 vs 3.5/day with placebo) and a 1.4-point severity improvement vs 0.3 for placebo, outperforming the two approved small‑molecule rivals. The company reported a favorable safety profile with no liver signal, positioning ABCL635 as a potential best‑in‑class non‑hormonal therapy. Analysts and investors cheered the data, boosting the stock, and AbCellera plans Week 12 readouts and Phase 3 development discussions.